Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

BACKGROUND: The purpose of this study was to compare clinical outcomes of Erlotinib versus Gefitinib in the treatment of Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and newly diagnosed brain metastases. METHODS: Consecutive Asian patients with exon 19 EGFR-mutant lung adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Ye, Zhang, Jing, Huang, Juanjuan, Xu, Bo, Li, Ning, Cao, Lei, Zhao, Mingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247515/
https://www.ncbi.nlm.nih.gov/pubmed/30458751
http://dx.doi.org/10.1186/s12890-018-0734-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247515/
https://www.ncbi.nlm.nih.gov/pubmed/30458751
http://dx.doi.org/10.1186/s12890-018-0734-1

Ejemplares similares